Prostate-specific membrane antigen (PSMA)-targeted PET imaging has changed the management of patients with prostate cancer (PCa). F18-PSMA is a novel PSMA ligand which progressively replaces the previously introduced Ga68-PSMA
Prostate-specific membrane antigen (PSMA)-targeted PET imaging has changed the management of patients with prostate cancer (PCa). F18-PSMA is a novel PSMA ligand which progressively replaces the previously introduced Ga68-PSMA
